NICE rules against first-line use of Ipsen’s Cabometyx
admin 5th June 2018 Uncategorised 0The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.
More: NICE rules against first-line use of Ipsen’s Cabometyx
Source: News